Caribou Biosciences Income Statement (2020-2025) | CRBU

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter)
1.59M1.48M3.98M2.56M2.66M4.19M3.30M3.69M3.50M3.75M23.66M3.56M2.43M3.46M2.02M2.08M2.35M2.67M2.20M3.94M
Operating items
Research & Development (Quarter)
10.16M12.33M15.83M15.11M13.92M22.58M19.99M25.74M25.71M26.50M28.58M31.28M33.79M35.48M30.42M30.46M35.53M27.69M22.40M23.82M
Selling, General & Administrative (Quarter)
4.60M5.11M6.76M7.85M9.59M10.04M9.85M8.53M8.91M10.12M9.71M9.72M14.64M11.48M9.84M10.49M9.73M10.40M9.20M8.58M
Other Operating Expenses (Quarter)
12.15M
Operating Expenses (Quarter)
14.76M17.44M22.59M22.96M23.52M32.62M29.84M34.27M34.62M36.62M38.30M41.00M48.43M46.97M40.26M40.95M45.27M50.24M31.60M32.39M
Operating Income (Quarter)
-13.18M-15.96M-18.62M-20.41M-20.85M-28.43M-26.54M-30.58M-31.12M-32.87M-14.63M-37.44M-46.00M-43.50M-38.24M-38.88M-42.91M-47.58M-29.40M-28.45M
EBIT (Quarter)
-13.18M-15.96M-18.62M-20.41M-20.85M-28.43M-26.54M-30.58M-31.12M-32.87M-14.63M-37.44M-46.00M-43.50M-38.24M-38.88M-42.91M-47.58M-29.40M-28.45M
Non-operating items
Non Operating Investment Income (Quarter)
-0.95M-0.49M
Interest & Investment Income (Quarter)
0.05M0.02M0.08M
Other Non Operating Income (Quarter)
0.02M0.07M0.04M0.26M0.70M1.47M2.33M2.83M3.05M4.77M4.82M4.46M4.01M3.72M5.31M2.59M2.19M1.85M2.20M
Non Operating Income (Quarter)
0.02M1.65M-2.36M2.25M1.76M1.73M-0.11M3.66M3.07M3.35M4.63M3.13M4.77M5.80M3.55M3.38M2.92M-6.52M1.85M1.42M
Net income details
EBT (Quarter)
-13.16M-14.31M-20.97M-18.16M-20.85M-28.43M-26.54M-30.58M-31.12M-32.87M-14.63M-37.44M-46.00M-43.50M-38.24M-38.88M-42.91M-47.58M-29.40M-28.45M
Tax Provisions (Quarter)
0.32M
Profit After Tax (Quarter)
-13.16M-14.31M-20.97M-18.48M-19.09M-26.70M-26.65M-26.99M-28.04M-29.52M-10.00M-34.51M-41.23M-37.70M-34.68M-35.49M-39.99M-54.10M-27.55M-26.49M
Equity Income (Quarter)
-0.09M-0.02M0.03M-0.06M-0.01M0.02M-0.00M-0.01M-0.10M-0.01M
Income from Continuing Operations (Quarter)
-13.16M-14.31M-20.97M-18.48M-20.85M-28.43M-26.54M-30.58M-31.12M-32.87M-14.63M-37.44M-46.00M-43.50M-38.24M-38.88M-42.91M-47.58M-29.40M-28.45M
Consolidated Net Income (Quarter)
-13.16M-14.31M-20.97M-18.48M-20.85M-28.43M-26.54M-30.58M-31.12M-32.87M-14.63M-37.44M-46.00M-43.50M-38.24M-38.88M-42.91M-47.58M-29.40M-28.45M
Income towards Parent Company (Quarter)
-13.16M-14.31M-20.97M-18.48M-20.85M-28.43M-26.54M-30.58M-31.12M-32.87M-14.63M-37.44M-46.00M-43.50M-38.24M-38.88M-42.91M-47.58M-29.40M-28.45M
Net Income towards Common Stockholders (Quarter)
-13.16M-14.31M-20.97M-18.48M-20.85M-28.43M-26.54M-30.58M-31.12M-32.87M-14.63M-37.44M-46.00M-43.50M-38.24M-38.88M-42.91M-47.58M-29.40M-28.45M
Additional items
EPS (Basic) (Quarter)
-1.39-1.39-0.46-0.31-0.32-0.44-0.44-0.45-0.46-0.48-0.12-0.40-0.46-0.42-0.38-0.39-0.43-0.58-0.30-0.28
EPS (Weighted Average and Diluted) (Quarter)
-1.39-0.460.09-0.32-0.44-0.44-0.45-0.46-0.48-0.12-0.40-0.46-0.42-0.38-0.39-0.43-0.58-0.30-0.28
Shares Outstanding (Weighted Average) (Quarter)
9.50M9.88M45.89M31.66M60.55M60.65M60.73M60.80M61.19M61.42M83.78M73.81M89.30M89.82M90.03M90.32M92.68M92.86M93.00M93.39M
Shares Outstanding (Diluted Average) (Quarter)
10.26M45.89M31.66M60.55M60.76M60.73M60.80M61.19M61.30M68.88M73.81M89.30M90.34M90.46M90.32M92.68M93.03M93.00M93.39M
EBITDA (Quarter)
-13.16M-14.31M-20.97M-18.61M-20.04M-27.19M-27.10M-26.47M-27.26M-29.93M-9.85M-33.49M-41.59M-37.69M-33.58M-36.02M-40.08M-54.23M-27.50M-26.48M
Interest Expenses (Quarter)
0.00M
Tax Rate (Quarter)
-1.77%